Skip to content

Author

S. Lonardi

We have 3 of 750 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Estimating the clinical benefit of metastases resection in liver-limited metastatic colorectal cancer: an IPD-based pooled analysis of nine randomized trials

Background In resected liver-limited metastatic colorectal cancer (LL-mCRC), disease-free survival (DFS) and postsurgical overall survival (psOS) have been found to be weakly related in heterogeneous retrospective series, challenging the role of DFS as a surrogate biomarker of psOS. Additionally, it remains unclear whe...

M. Germani, A. Taravella, D. Rossini et al. · 0 citations
Open access Oct 2026

The impact of PROgnostic SIgnatures in stage II colon cancer patients enrolled in the phase III clinical trial TOSCA: the PROSIT study.

BACKGROUND Adjuvant chemotherapy (ACT) indication in stage II colorectal cancer (CRC) remains challenging, as clinical, pathological, and ctDNA inadequately predict benefit. Immune infiltration correlates with outcome, yet transcriptional signatures have not been systematically evaluated in prospective trial cohorts. W...

A. Puccini, Lorenzo Ferrando, G. Frige' et al. · 0 citations
Aug 2026

Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC.

High baseline circulating and tumor γδ T cells and early circulating CD8⁺PD-1⁺ T Cell expansion were associated with better outcome under AtezoBev, and an early induction of T cell-associated interferon-γ signaling at 3 weeks after the first injection of AtezoBev in patients that experienced response.

I. Galy-Fauroux, A. Asif-Laidin, M. Evain et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.